Full video transcriptClick to expand
Auto-generated transcript of @creativelywell's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Hey y'all, I know I'm so late with telling y'all this
- 0:04But this is my first month
- 0:06On wagovi and working with my trainer exercising changing my eating
- 0:11not always to a hundred percent on either but
- 0:15Results results look at let's look at the food, but first
- 0:18I'm so proud of my little food for going down baby
- 0:22My face
- 0:23Quarters all face what all right. All right. Let's get into let's get to decide. Hold on
- 0:28Okay, now let's let's talk about this tummy
- 0:31Let's talk about this tummy and my booty my booty came up a little bit
- 0:35like my face looks small like
- 0:39My little I can cook elbow. It's trying to go down a little bit. Oh my god. Okay. Okay. Okay. Let's get to the back real quick
- 0:47Let's take it in let's let's acknowledge the results. Okay. Let's acknowledge
- 0:52One month and I got to keep it going. I want to see what two months looks like. Oh my god
- 0:58You
Wegovy before-and-after videos: what TikTok gets wrong
Quick answer
The creator is one month into semaglutide 2.4 mg (Wegovy) combined with supervised exercise and dietary modification, which mirrors the protocol used in the STEP 1 trial that produced 14.9% average weight reduction over 68 weeks. At four weeks, she is likely still in the early titration phase of the medication, meaning appetite suppression effects may be partial and peak efficacy has not yet been reached. Her self-reported inconsistency with diet and exercise is consistent with real-world adherence data, where perfect compliance is uncommon but partial adherence still produces meaningful outcomes when combined with a GLP-1 agonist.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Wegovy before-and-after videos: what TikTok gets wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Wegovy before-and-after videos: what TikTok gets wrong" from Chantel🧡Creative Wellness🧡. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is one month into semaglutide 2.
The reason this review is not generic is the source wording and the canonical claim label "glp1 greenscreen wegovy wegovyweightloss weightloss beforeandafte." In this clip, the useful excerpt is: "Hey y'all, I know I'm so late with telling y'all this But this is my first month On wagovi and working with my trainer exercising changing my eating not always to a hundred percent on either but Results results look at let's look at the..." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is one month into semaglutide 2.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is one month into semaglutide 2.4 mg (Wegovy) combined with supervised exercise and dietary modification, which mirrors the protocol used in the STEP 1 trial that produced 14.9% average weight reduction over 68 weeks. At four weeks, she is likely still in the early titration phase of the medication, meaning appetite suppression effects may be partial and peak efficacy has not yet been reached. Her self-reported inconsistency with diet and exercise is consistent with real-world adherence data, where perfect compliance is uncommon but partial adherence still produces meaningful outcomes when combined with a GLP-1 agonist.
- STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% average weight loss over 68 weeks on semaglutide 2.4 mg, meaning one-month results are early and not the ceiling.
- Adding exercise and dietary changes to semaglutide amplifies outcomes: Davies et al. (2021, Lancet) found the combination consistently outperformed drug alone.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% average weight loss over 68 weeks on semaglutide 2.4 mg, meaning one-month results are early and not the ceiling.
- Adding exercise and dietary changes to semaglutide amplifies outcomes: Davies et al. (2021, Lancet) found the combination consistently outperformed drug alone.
- Early weight changes at four weeks partly reflect glycogen and water loss, not only fat reduction, so visual one-month results can be somewhat misleading about long-term trajectory.
- 44% of semaglutide users in STEP 1 reported nausea, 24.5% reported vomiting, and 30% reported diarrhea. Side effect profiles are absent from this video entirely.
- STEP 5 (Garvey et al., 2022, Nature Medicine) found that stopping semaglutide led to recovery of roughly two-thirds of lost weight within one year, meaning long-term use or a maintained lifestyle change is required to preserve results.
- Wegovy requires a titration schedule of 16 to 20 weeks to reach the full 2.4 mg weekly dose. One-month users are still in early dosing and have not yet experienced peak appetite suppression.
- Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. Medical evaluation before starting is not optional.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @creativelywell actually say?
She shared a one-month before-and-after while on Wegovy, combined with working with a trainer, changing her eating habits, and exercising. Her words were refreshingly honest: "not always to a hundred percent on either." She pointed to visible changes in her face, stomach, and back, and said she wants to see what two months looks like. That's the whole claim: Wegovy plus lifestyle changes produced noticeable physical changes in 30 days.
No wild medical promises. No "this cured my insulin resistance" language. Just a person showing their body in progress and expressing genuine surprise at what she saw. That context matters when we evaluate this.
Does the science back this up?
Yes, the general direction of her results is supported by evidence, though one month is early and individual variation is real. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) followed 1,961 adults on semaglutide 2.4 mg weekly for 68 weeks and found an average body weight reduction of 14.9% versus 2.4% for placebo. That's the long game.
At the one-month mark, results vary significantly. Some participants in STEP trials reported early losses in the first four weeks, but the drug typically reaches its maintenance dose over 16 to 20 weeks via a titration schedule. What she's seeing at month one is likely a combination of the drug's early appetite-suppressing effects, reduced caloric intake, and the lifestyle changes she mentioned. Davies et al. (2021, Lancet) found that adding exercise and dietary changes to semaglutide meaningfully amplified outcomes compared to drug alone. She's doing the combination correctly.
What did they get wrong (or right)?
Mostly right, with one thing worth watching. She got credit for being upfront that she wasn't perfect with food or exercise. That kind of honesty is rare in weight loss content and actually reflects how most real-world users experience these medications.
What deserves a flag: visible one-month results on GLP-1 medications can create unrealistic expectations for others. The STEP trials showed that peak weight loss occurs around weeks 60-68 for most participants. Early results, especially facial slimming, are often partially attributed to water and glycogen reduction, not just fat loss. She didn't say anything technically wrong, but viewers should know that her results at month one are not a ceiling. They're also not a guarantee for anyone else.
One more thing: she doesn't mention side effects at all. The STEP 1 trial reported nausea in 44% of the semaglutide group, vomiting in 24.5%, and diarrhea in 30%. That silence doesn't make her video harmful, but it's a gap in the full picture.
What should you actually know?
If you're watching this video and thinking Wegovy is a simple fix, slow down. The drug works through GLP-1 receptor agonism, reducing appetite and slowing gastric emptying. But it is a prescription medication with a structured titration schedule, a list of contraindications including personal or family history of medullary thyroid carcinoma, and a side effect profile that stops a meaningful percentage of users from continuing.
The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed that most weight regain occurs within one year of stopping the medication, with participants recovering roughly two-thirds of lost weight by month 120 post-treatment. That's not an argument against using it. It is an argument for understanding what you're signing up for before month one becomes year two.
Her combination approach, drug plus trainer plus dietary changes, is actually what the clinical literature recommends. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed lifestyle intervention plus pharmacotherapy consistently outperformed either alone. She's doing this the right way, even if she's not citing the research herself.
Is this video responsible content?
By TikTok weight loss standards, this is actually one of the more grounded videos out there. She's not selling anything. She's not claiming Wegovy will work for everyone. She's documenting her own experience with visible, modest results and a realistic tone. The main gap is the absence of any mention of side effects or the long-term commitment the medication requires. Viewers who see this and assume month one results are typical or that the drug requires no medical supervision are drawing conclusions the video didn't earn for them. That's a user literacy problem more than a creator honesty problem.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Chantel🧡Creative Wellness🧡 · TikTok creator
182.8K views on this video
#greenscreen #wegovy #wegovyweightloss #weightloss #beforeandafter
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about step 1 trial (wilding et al., 2021, nejm) showed 14.9%?
STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% average weight loss over 68 weeks on semaglutide 2.4 mg, meaning one-month results are early and not the ceiling.
What does the video say about adding exercise?
Adding exercise and dietary changes to semaglutide amplifies outcomes: Davies et al. (2021, Lancet) found the combination consistently outperformed drug alone.
What does the video say about early weight changes at four weeks partly reflect glycogen?
Early weight changes at four weeks partly reflect glycogen and water loss, not only fat reduction, so visual one-month results can be somewhat misleading about long-term trajectory.
What does the video say about 44% of semaglutide users in step 1 reported nausea, 24.5%?
44% of semaglutide users in STEP 1 reported nausea, 24.5% reported vomiting, and 30% reported diarrhea. Side effect profiles are absent from this video entirely.
What does the video say about step 5 (garvey et al., 2022, nature medicine) found?
STEP 5 (Garvey et al., 2022, Nature Medicine) found that stopping semaglutide led to recovery of roughly two-thirds of lost weight within one year, meaning long-term use or a maintained lifestyle change is required to preserve results.
What does the video say about wegovy requires a titration schedule of 16 to 20 weeks?
Wegovy requires a titration schedule of 16 to 20 weeks to reach the full 2.4 mg weekly dose. One-month users are still in early dosing and have not yet experienced peak appetite suppression.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Chantel🧡Creative Wellness🧡, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.